RXRX Recursion Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RXRX

Price (delayed)

$3.7

Market cap

$2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1

Enterprise value

$1.52B

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 10
Highlights
The company's EPS rose by 45% YoY and by 14% QoQ
The debt has declined by 24% year-on-year and by 8% since the previous quarter
The gross margin has surged by 200% year-on-year but it has dropped by 51% since the previous quarter
Recursion Pharmaceuticals's gross profit has soared by 184% YoY but it has plunged by 60% from the previous quarter
RXRX's revenue is down by 17% since the previous quarter and by 15% year-on-year
RXRX's equity is down by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.recursion.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RXRX

RXRX stock price

How has the Recursion Pharmaceuticals stock price performed over time
Intraday
-8.64%
1 week
15.99%
1 month
5.71%
1 year
-23.08%
YTD
-9.54%
QTD
0.82%

Financial performance

How have Recursion Pharmaceuticals's revenue and profit performed over time
Revenue
$54.86M
Gross profit
$1.91M
Operating income
-$544.01M
Net income
-$518.88M
Gross margin
3.5%
Net margin
-945.9%
The gross margin has surged by 200% year-on-year but it has dropped by 51% since the previous quarter
Recursion Pharmaceuticals's gross profit has soared by 184% YoY but it has plunged by 60% from the previous quarter
Recursion Pharmaceuticals's net income has increased by 20% YoY and by 7% from the previous quarter
RXRX's revenue is down by 17% since the previous quarter and by 15% year-on-year

Price vs fundamentals

How does RXRX's price correlate with its fundamentals

Growth

What is Recursion Pharmaceuticals's growth rate over time

Valuation

What is Recursion Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.14
P/S
35.91
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.65
The company's EPS rose by 45% YoY and by 14% QoQ
RXRX's price to book (P/B) is 29% lower than its 5-year quarterly average of 3.3 but 24% higher than its last 4 quarters average of 1.9
RXRX's equity is down by 11% since the previous quarter
RXRX's price to sales (P/S) is 42% lower than its 5-year quarterly average of 67.2 but 17% higher than its last 4 quarters average of 33.6
RXRX's revenue is down by 17% since the previous quarter and by 15% year-on-year

Efficiency

How efficient is Recursion Pharmaceuticals business performance
Recursion Pharmaceuticals's return on equity has increased by 34% YoY and by 7% QoQ
Recursion Pharmaceuticals's return on assets has increased by 29% YoY and by 6% QoQ
The company's return on sales fell by 12% QoQ but it rose by 5% YoY
RXRX's ROIC is down by 8% YoY but it is up by 3.6% QoQ

Dividends

What is RXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RXRX.

Financial health

How did Recursion Pharmaceuticals financials performed over time
The company's current ratio rose by 41% YoY but it fell by 8% QoQ
The quick ratio has grown by 41% year-on-year but it has declined by 9% since the previous quarter
The debt is 93% smaller than the equity
RXRX's debt to equity is down by 30% year-on-year
The debt has declined by 24% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.